ArticleImmunity2024
Oligoadenylate synthetase 1 displays dual antiviral mechanisms in driving translational shutdown and protecting interferon production.
Article in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- Alternative splicing broadens antiviral diversity at the human OAS2 locus.The EMBO journal · 2026Article
- Lost in translation: interferon-stimulated genes targeting flavivirus protein synthesis.Journal of virology · 2026Review
- Immune gene expression dynamics across the lifespan of Tibetan macaques (Current zoology · 2026Article
- Integration of single-cell cis-expression quantitative trait locus and Mendelian randomization analyses identifies a Treg-specific gene for precision therapy in rheumatoid arthritis, gonarthrosis, and gouty arthritis.The Journal of international medical research · 2026Article
- RNA-binding proteins and ribonucleoproteins as determinants of immunity.Nature reviews. Immunology · 2026Review
- Sleep Maintenance Insomnia in Older Adults: Cardiometabolic Comorbidities and Evidence of Antiviral Pathways Activation from Blood Transcriptome and dsRNA Expression Analyses.International journal of molecular sciences · 2026Article
- FGFR signaling and neddylation facilitate SARS-CoV-2 infection by modulating interferon induction and viral entry, respectively.iScience · 2026Article
- Beyond Viral Restriction: The Metabolic Dimensions of Interferon-Stimulated Genes in Antiviral Immunity.Viruses · 2026Review
- Article
- The OAS-RNase L pathway: Insights from experiments of nature.Science immunology · 2026Review
- Article
- Review
- The function and mechanism of protein acylation in the regulation of viral infection.Virulence · 2025Review
- Condensation of human OAS proteins initiates diverse antiviral activities in response to West Nile virus.Genes & development · 2025Article
- Interferons in health and disease.Cell · 2025Review
- A Novel Microencapsulated Bovine Recombinant Interferon Tau Formulation for Luteolysis Modulation in Cattle.Biomolecules · 2025Article
- Deep Proteomics Analysis Unravels the Molecular Signatures of Tonsillar B Cells in PFAPA and OSAS in the Pediatric Population.International journal of molecular sciences · 2025Article
- Finding a foothold to fight: New insights into the viral RNA sensing and activation mechanism of OAS2.Molecular cell · 2025Article
- West Nile Virus (WNV): One-Health and Eco-Health Global Risks.Veterinary sciences · 2025Review
- RNase L represses hair follicle regeneration through altered innate immune signaling.The Journal of clinical investigation · 2025Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 5 institutions in 2 countries.
Funding
Abstract
In response to viral infection, how cells balance translational shutdown to limit viral replication and the induction of antiviral components like interferons (IFNs) is not well understood. Moreover, how distinct isoforms of IFN-induced oligoadenylate synthetase 1 (OAS1) contribute to this antiviral response also requires further elucidation. Here, we show that human, but not mouse, OAS1 inhibits SARS-CoV-2 replication through its canonical enzyme activity via RNase L. In contrast, both mouse and human OAS1 protect against West Nile virus infection by a mechanism distinct from canonical RNase L activation. OAS1 binds AU-rich elements (AREs) of specific mRNAs, including IFNβ. This binding leads to the sequestration of IFNβ mRNA to the endomembrane regions, resulting in prolonged half-life and continued translation. Thus, OAS1 is an ARE-binding protein with two mechanisms of antiviral activity: driving inhibition of translation but also a broader, non-canonical function of protecting IFN expression from translational shutdown.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.